Loading clinical trials...
Loading clinical trials...
A Phase I/II, Open-label, Multi-center Study of the Safety and Efficacy of BLZ945 as Single Agent and in Combination With PDR001 in Adults Patients With Advanced Solid Tumors
Conditions
Interventions
BLZ945
PDR001
Locations
14
United States
Dana Farber Cancer Institute Dana Farber Cancer Institute
Boston, Massachusetts, United States
Sarah Cannon Research Institute Sarah Cannon Research
Nashville, Tennessee, United States
UT M.D Anderson Cancer Center
Houston, Texas, United States
Mays Cancer Ctr Uthsa Mdacc
San Antonio, Texas, United States
Novartis Investigative Site
Tel Aviv, Israel
Novartis Investigative Site
Rozzano, MI, Italy
Start Date
October 21, 2016
Primary Completion Date
December 1, 2022
Completion Date
December 1, 2022
Last Updated
January 18, 2024
NCT06898450
NCT05719558
NCT07029399
NCT04826341
NCT06819735
NCT06760819
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions